Anti-BCCIP / BRCA2 and CDKN1A-interacting protein

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. BCCIP antibody detects BRCA2 and CDKN1A-interacting protein, a nuclear protein involved in DNA repair, cell cycle regulation, and genome maintenance. Encoded by the BCCIP gene on chromosome 10q26.2, this protein interacts with BRCA2 and p21 (CDKN1A) to facilitate homologous recombination and checkpoint control. BCCIP functions as a cofactor in the BRCA2-RAD51 repair complex, promoting the repair of double-strand breaks and ensuring replication fork stability during DNA synthesis.Structurally, BCCIP contains conserved coiled-coil domains and an acidic region that mediate protein-protein interactions with DNA repair and replication factors. It is expressed in proliferating cells and localizes primarily to the nucleus, particularly at sites of DNA damage. Through its association with p21, BCCIP also influences CDK activity and contributes to G1/S and G2/M checkpoint control.The BCCIP antibody is widely used in DNA repair, oncology, and cell cycle research to study BRCA2-associated homologous recombination and genomic integrity. Western blot analysis identifies a 36 kilodalton band corresponding to BCCIP, while immunofluorescence shows nuclear punctate staining consistent with DNA damage foci. This antibody enables detection of repair complex dynamics and checkpoint activation in mammalian cells.Dysregulation of BCCIP expression impairs DNA repair fidelity, leading to chromosomal instability, replication stress, and increased tumor susceptibility. Reduced BCCIP levels have been observed in glioblastoma and colorectal cancer, supporting its role as a tumor suppressor. The BCCIP antibody provides a reliable reagent for exploring DNA damage response and tumorigenic mechanisms. NSJ Bioreagents validates this antibody for western blotting, immunohistochemistry, and immunofluorescence, ensuring consistent results for genomic stability studies.